Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05929976 · ClinicalTrials.gov registry record
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
A clinical trial of Acute Lymphoblastic Leukemia and Genetic Predisposition, sponsored by Columbia University.
- Recruiting
- Registry status
- 4,900
- Enrollment target
- 8
- Study locations
NCT05929976 is a study of Acute Lymphoblastic Leukemia and Genetic Predisposition that is actively recruiting participants, run by Columbia University. The registered enrollment target is 4,900 participants, above the 345-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (1320% higher). The trial reports 8 study locations across 3 states.
The verdict
NCT05929976, a study of Acute Lymphoblastic Leukemia and Genetic Predisposition, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 4,900 participants
- Enrollment target
- 8
- Study locations
Study Summary
Nutritional status is a measurable and modifiable factor that is often not considered during treatment and its clinical impact undervalued due in part to the heavy demands on clinicians in low and middle income countries to deliver therapy to large numbers of patients. The proposed study will create a biobank of clinical data and biological specimens which will foster future studies on cancer progression and prognosis as well as toxicities during treatment which may impact survivorship and late-effects. Eligible patients must be between 3 years and 18 years of age at time of assent/consent, have newly diagnosed B- or T-cell acute lymphoblastic leukemia or mixed phenotype acute leukemia confirmed by pathology report, and must be receiving treatment at one of the participating centers. Patients receiving hematopoietic cell transplant will be excluded. Institutions were selected to ensure representation of several global health indicators related to nutritional status and wealth classification according to the World Bank. Data related to demographic variables (socioeconomic status, food security), lifestyle habits (diet, physical activity), nutritional anthropometrics (height, weight and arm anthropometry), and nutritional biological indices (stool and blood) will be collected at designated timepoints throughout treatment and one year after the end of treatment.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (8)
Other
- Hospital de Cancer Infanto Juvenil de Barretos - Barretos
- Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) - Recife
- Instituto de Tratamento do Câncer Infantil (ITACI) - São Paulo
- Unidad Nacional De Oncologia Pediatrica - Guatemala City
- Hospital Escuela - Tegucigalpa
- Post-Graduate Institute of Medical Education and Research (PGIMER) - Chandigarh
New York
- Columbia University Irving Medical Center - New York
Dar es Salaam Region
- Muhumbili Hospital - Dar es Salaam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,900 participants |
| Start Date | 2022-10-26 |
| Est. Completion | 2029-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05929976
The ClinicalTrials.gov registry entry for NCT05929976 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 4,900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 345-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (1320% higher). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT05929976 reports 8 study locations spanning 3 distinct geographic areas - top geographies include Other, New York, Dar es Salaam Region.
Frequently Asked Questions
What is clinical trial NCT05929976 about?
NCT05929976 is a clinical study titled "InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort". Nutritional status is a measurable and modifiable factor that is often not considered during treatment and its clinical impact undervalued due in part to the heavy demands on clinicians in low and middle income countries to deliver therapy to large numbers of patients. The proposed study will create...
What is the current status of trial NCT05929976?
This trial is currently recruiting. The enrollment target is 4,900 participants. The study started on 2022-10-26. Estimated completion is 2029-10-01.
What conditions does trial NCT05929976 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Genetic Predisposition, Microtia, Nutrition Aspect of Cancer.
What interventions are being tested in trial NCT05929976?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT05929976?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05929976 being conducted?
This trial has 8 study locations across New York, Dar es Salaam Region. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
RECRUITING · Phase 1
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RECRUITING · Phase 1
-
Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.